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Abstract
Acute respiratory distress syndrome (ARDS) is a severe complication which
affects thousands of patients every year and is associated with high mortality rates and
increased healthcare costs. A systematic review was conducted to determine the efficacy
of various interventions used to decrease the staggering mortality rate of ARDS. The
interventions studied were extracorporeal membrane oxygenation (ECMO), prone
positioning, and neuromuscular blockade. Data bases searched were Google Scholar,
PubMed, Cochrane library, and the CINAHL databases to find relevant research articles
and a literature review conducted. A total of 21 articles were considered and screened for
inclusion/exclusion criteria, ultimately yielding five articles included in this systematic
review. To guide this major project, the Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) checklist and flow diagram were utilized. To further assess the
quality of reach study, the Critical Appraisal Skills Programme (CASP) checklist was
used. A cross study analysis was performed to compare identified outcomes. This
systematic review determined one study to be underpowered, one study demonstrated a
decrease in mortality in the intervention group but was not statistically significant, and
two studies were stopped for futility. One study was adequately powered and displayed a
significant decrease in mortality rate. The results of this systematic review indicates
further research is needed on the efficacy of interventions to decrease ARDS-related
mortality and guide advanced practice nurse decision-making.
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Interventions to Decrease Mortality Among Patients with Acute Respiratory Distress
Syndrome
Background/Statement of the Problem
Acute Respiratory Distress Syndrome (ARDS) is an acute, life-threatening
condition requiring intensive care unit (ICU) level of care and technology. ARDS reflects
poor oxygenation and non-compliant lungs due to capillary endothelial injury and diffuse
alveolar damage (Patel et al., 2019). An international study involving 29,144 patients
revealed 10% of individuals admitted to the ICU and 23% of patients who were
mechanically ventilated were diagnosed with ARDS, with a morality rate as high as 46%
(Thompson et al., 2017). Other recent research has reported mortality rate of ARDS at
approximately 40-50% with up to 150,000 cases being diagnosed in the United States
annually (El-Haddad et al., 2017). These authors further describe factors that may impact
the mortality outcome prediction for this population such as the diagnosis of cancer, body
mass index, age, a diagnosis of diabetes mellitus, and gender. Thompson et al. (2017)
states that ARDS is likely unreported in low-income countries and may be
underrecognized in high-income countries. Therefore, the data available indicates the
problem may be larger than can be quantified.
Etiologies responsible for ARDS are vast with no single therapy or medication
proven to combat the high mortality rates. To compound the difficulties associated with
ARDS, diagnosis relies on chest radiologic images and clinical presentation only; no
designated biomarkers have yet been validated (Thompson et al., 2017). These authors
note that genetic susceptibility is highly suspected, however, and that patients with
clinical risk factors, such as sepsis, pneumonia, or trauma, do not necessarily develop
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ARDS. Some symptoms that manifest consist of cyanosis, diffuse crackles, dyspnea,
tachycardia, tachypnea and diaphoresis (Norris, 2019).
Treatment of ARDS patients, including neuromuscular blockade, low volume,
low pressure ventilator settings, and cautious fluid management have been extensively
studied and explored. This literature review will survey the current information regarding
three common interventions chosen to support these patients. Prone therapy is utilized to
maximize the use of viable lung tissue with the use of safe mechanical ventilator settings
without causing further lung injury. Another option is extracorporeal membrane
oxygenation (ECMO) therapy, which requires a more invasive, extravascular cannulation
system designed to improve oxygenation and ventilation while reducing lung injury
induced by mechanical ventilation. Neuromuscular blockade is an alternative intervention
as well, utilizing a prescribed infusion of a sedative to decrease the accumulation of
alveolar fluid, work of breathing, and dyssynchrony with the ventilator. Benefits, risks,
limitations, and notably high mortality rates occur with each intervention leaving a large
area of debate regarding which intervention benefits this population. Therefore, the
purpose of this study is to compare best evidence regarding the treatment options, prone
therapy, ECMO therapy, and neuromuscular blockade in decreasing mortality rates for
adult patients with ARDS. The next section will discuss the review of the literature.
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Literature Review
Pathophysiology and Definition
ARDS is the most severe form of acute lung injury (ALI), and defining signs and
symptoms of capillary endothelial injury and diffuse alveolar damage are thus more
pronounced (Norris, 2019). Lung tissue alterations increase the permeability of the
alveoli sacs which allows for other fluid and substances from the capillary, such as blood
cells and proteins to enter into the area originally designated for gas exchange only. The
resulting abnormalities in surfactant production cause alveolar collapse and further
compromise gas exchange. This alteration in permeability allows for accumulation of
impervious fluids and diminishes adequate surface area to optimize the intake of oxygen
(O2) and release of carbon dioxide (CO2). Once progression ensues, the lungs also
become less elastic, stiff, and ultimately more difficult to inflate. With the alignment of
these detrimental factors, ventilation (V) and perfusion (Q) are no longer adequate and
reciprocal and is noted as a VQ mismatch. Patients with ARDS display intrapulmonary
shunting of blood, diminished gas exchange, and refractory hypoxemia despite receiving
the highest levels of supplemental O2 (Norris, 2019).
Additionally, in the setting of ARDS, alveolar macrophages act as defense against
pathogenic microorganisms and release strong proinflammatory mediators, such as
cytokines, which characteristically build up and contribute to further tissue damage
(Carlucci et al., 2014). Lastly, dead space is often measured in studies regarding ARDS.
Dead space accounts for the air trapped in spaces when there is decreased diffusion,
which is normal; however, in ARDS, dead space is more extensive, leading to the
diminished oxygenation and increased mortality risk (Kallet et al., 2017).
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Diagnosing severe ARDS is identified by mechanical ventilator settings and is
defined as a PaO2:FiO2 ratio of <150 mm Hg, with an FiO2 of ≥0.6, a PEEP of ≥5 cm of
water, and a tidal volume of about 6 ml per kilogram of predicted body weight, which is
consistent with the American-European Consensus Conference criteria (Guérin, et al.,
2013). PaO2 represents partial pressure of arterial oxygen, which is normally between 75100 mm Hg (Ferri 2019 p. 146). The normal percentage of the FiO2 in the air we breathe
is approximately 21% while ventilated patients are receive 21% to 100%, depending on
patient-specific requirements. Positive end expiratory pressure (PEEP) is additionally
used to keep alveoli open and provide a prescribed amount of pressure to force
oxygenated air into the lung tissue, thereby increasing alveolar recruitment and
preventing collapse (Gattinoni et al., 2017). Of note, the benefit of alveolar recruitment is
that once the alveoli are properly inflated, there is an increase in surface area in the lungs
which allows for improved gas exchange (Marino, 2014). Elevated settings of PEEP and
tidal volume are often pushed to their limits to gain sufficient oxygenation in the noncompliant lung; however, such elevations place the patient at risk for suffering lung
injury. Prone therapy, ECMO, and neuromuscular blockade are used as a solo therapy or
used together to minimize these mechanical ventilation associated risks.
Etiologies
Several physiologic events and illnesses can lead to the development of ARDS,
making the prediction of its occurrence difficult to identify at the early stages, or
sometimes at all. Direct causes, such as inhalation injuries gained from exposure to fire
related smoke or aspiration, may be responsible for initiating the devastating respiratory
disorder. Anything that causes inflammation within the patient also poses a risk for
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ARDS as well, including sepsis, pancreatitis, influenza virus, pneumonia, drug or toxin
reaction, and trauma (Norris 2019). No matter which process initiates severe ARDS in a
patient, it results in excessive ventilation relative to pulmonary capillary blood flow,
which increases dead space ventilation, and less gas exchange with each breath (Marino,
2014). One statistical analysis concluded that the fraction of pulmonary dead space
serves as an indicator of mortality risk and further, that pulmonary dead space fraction
varies from etiology to etiology (Kallet et al., 2017).
Prone Therapy
For decades, prone therapy has been utilized to facilitate improved outcomes in
the survival of ARDS patients. Quite literally, the patient is flipped to a prone position in
bed to optimize oxygenation to a greater portion of lung tissue in the ICU setting.
Regarding lung recruitment, Kallet et al. (2015) notes that the prone position and proper
PEEP have an additive effect which lessen the chances for ventilator associated lung
damage. The authors emphasize the importance of utilizing the greater portion of lung
tissue, since approximately 50% of lung tissue is oriented to the dorsal plane of an adult,
whereas only 20% is oriented to the ventral portion. With increased surface area of the
alveoli employed, more fluid reabsorption is possible, lessening the notable pulmonary
edema which is excess fluid accumulation in the lungs inhibiting optimal oxygenation
(Norris, 2019). Prone maneuvering also encourages a more homogenous distribution of
trans-pulmonary pressure within each alveolus (Kallet, 2015).
Attempts have been made to capitalize on the benefits from position changes in
patients with ARDS. Robak et al. (2011) directed a prospective randomized control study
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of 20 adult patients with ARDS and the use of prone positioning to improve PaO2/FiO2
ratio. When compared to supine positioning, a positive response in the ratio was detected
in 14 (70%) of patients in the prone position, whereas 17 patients (85%) had responded to
prone plus the upright positioning. Though this study reported improved oxygenation,
some study limitations diminish the integrity of the findings. The lack of a more robust
sample discredited the findings, since only 20 patients were included in the study. The
choice to alternate patient positions from supine, to prone, to upright in two- to six-hour
increments also weakened the study. In addition, mortality rate was not specifically
measured in this study.
Additional research of adult patients with ARDS investigated the use of prone
therapy in those sharing the same etiology. Mutkule et al. (2016) examined six
individuals with ARDS who were diagnosed with H1N1 and received prone therapy
treatment to decrease mortality rates. In the beginning of the study, 43 patients were
swabbed and positive for H1N1, however only 17 required mechanical ventilation. Of the
17 patients, 11 improved with typical ventilation settings after 12 hours. Six of the
remaining patients continued to demonstrate a low PaO2/FiO2 ratio and were
subsequently proned for 16 hours followed by 8 hours in the supine position. Until the
patient maintained a PaO2/FiO2 ratio greater than 150, the 16-hour prone/8-hour supine
pattern continued. The authors conclude the average ICU length of stay was 11.16 days
and that there were no deaths at day 28 and 90. Ultimately, the study yielded results
which ultimately proved to be inadequate. Etiology of ARDS is far too varied to
represent a sample which only included those simultaneously diagnosed with H1N1
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virus. Outcomes will likely vary in ARDS patients depending on etiology (Kallet et al.,
2017) and thus cannot be included in the systematic review.
Another aspect of ARDS is considered by Kallet (2015) who writes that recent
evidence of PaO2 and PaCO2 (partial pressure of arterial carbon dioxide) responders in
prone therapy reflect the extent and distribution of lung injury, rendering the impact of
alveolar ventilation improvement using prone positioning less consistent. Further analysis
of prone therapy and its benefits and setbacks are required, and lower mortality rates in
patients with ARDS are required.
Manual vs. Automatic Prone Therapy
Instead of manual proning, some institutions have utilized automatic prone
therapy with a specialty bed which maintains the patient between two mattresses and flips
them from supine to prone and back to supine at prescribed intervals. This specialty
mattress is not one undivided surface, but several secured, cushioned pieces which are
able to be unlatched individually for nursing assessments. Additionally, while prone, the
bed slowly tips the patient to the right and the left at pre-programmed angles. Locating
studies to determine the efficacy of this intervention proved to be difficult and sparse.
A retrospective, descriptive-comparative approach was constructed in recent years
to determine the effects of automatic versus manual prone therapy on patient outcomes.
Morata et al. (2017) analyzed 24 months of data and a total of 37 adult subjects who met
the ARDS criteria. Of these patients, 16 received manual therapy and 21 received
automatic therapy. The authors analyzed variables such as demographic information,
hospital length of stay (LOS), ICU LOS, discharge disposition, and complications.
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Ultimately, those who were manually proned had a reduction in ICU LOS and hospital
LOS, were discharged to home in greater numbers, and had fewer complications. The
complications noted were pressure injuries, which were the most common, and tube and
line dislodgement. Automatic prone therapy did not prove to be more useful than manual
proning in this study, meaning that utilizing the prone therapy mattress or a team of staff
to prone the patient will produce similar outcomes. Larger, randomized control trials are
warranted to create more meaningful data and to produce more conclusive results.
ECMO therapy
Extracorporeal Membrane Oxygenation (ECMO) therapy provides respiratory and
cardiac support, aiding in gas exchange and perfusion. The first documented use of
ECMO in rescue therapy for ARDS dates back to 1972 according to Parekh et al (2018).
This therapy incorporates an assembly of machines, such as a pump, a control panel, a
blender and an oxygenator, to pump blood in and out of the patient. This is done by way
of a single or double lumen venous cannulation system or a venous-arterial system with
three cannulations. In patients with severe ARDS, the two-fold benefit from ECMO is to
first confirm satisfactory oxygenation and ventilation, and second, to reduce ventilatorinduced lung injury by facilitating low-volume, low-pressure ventilation. (Parekh et al.,
2018).
A retrospective case-control study was conducted to compare outcomes of adult
patients diagnosed with ARDS who received ECMO for treatment and those who did not
(Tsai et al., 2015). The choice to treat or not treat with ECMO was based on the Acute
Physiologic and Chronic Health Evaluation II (APACHE II) score and age. The
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researchers originally sampled 216 patients, however, after the APACHE II screening,
the author’s sampled 45 ECMO and 45 non-ECMO ARDS patients. There was no
substantial difference in the PaO2/FiO2 ratio in either group. The ECMO group did,
however, exhibit a lower mortality rate than its counter group (55% vs. 65.1%,
respectively). Although improvements in oxygenation and survival rates were illustrated
in this case, the sample size was relatively small (90 patients) and it took place in one
healthcare facility only.
ECMO therapy was endorsed as treatment in a case-control study which involved
15 cases between 2010-2016, totaling 52 adult patients with ARDS (Muñoz, et al., 2017).
This research identified increased survival in ARDS patients when treated with ECMO,
displaying a mortality rate of 47% vs. non-ECMO 77%. However, longer inpatient stays
and complications due to user error/insufficient training were demonstrated. Four patients
died due to complications related to ECMO therapy. Again, though ECMO provided a
better chance of decreasing mortality, the odds of surviving are still low.
Neuromuscular Blockade
Inducing paralysis via pharmacologic measures may aid in the reduction of
mortality rates among individuals with ARDS. In the setting of appropriate
neuromuscular blockade delivery, one expects increased compliance between the
ventilator and the patient, decreased work of breathing, and less fluid accumulation in the
alveoli. Ultimately, this should result in a reduction of ventilated days, less time spent in
the ICU, less barotrauma, and benefit overall mortality rates. Various paralytics can be
chosen to attain these goals. Challenges surrounding this method include selection of the
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correct paralytic, correct dose, accurate monitoring, such as with the train of four (TOF),
and risk of residual neuromuscular weakness (Merkel et al., 2019). The TOF is a standard
method in monitoring drug induced paralysis by applying two electrodes to the skin at the
ulnar nerve, delivering four low frequency electrical impulses, then observing for a
twitch, demonstrated as a brief adduction of the thumb (Marino, 2014). This establishes a
baseline response for the nurse to subsequently titrate the drug to achieve paralysis
safelty.
Duration of neuromuscular blockade therapy may impact outcomes in ARDS
patients as well. A retrospective review was conducted on adults with ARDS in a surgical
intensive care unit to establish whether cisatricurium infusion under 48 hours (SHORT)
or for longer periods of time (LONG) affected mortality rate. Beyond the 48-hour
window of time, paralytic administration has not been evaluated due to increased concern
for severe complications, such as neuromuscular dysfunction, weakness, increase in ICU
days, and greater time spent on a ventilator. Out of the selected 73 patients, 32 (44%)
were in the SHORT group and 41 (56%) were entered into the LONG group. The
demographics of both groups were comparable except that the SHORT study contained
slightly older patients. Overall, 60% mortality was observed, and similar occurrences of
deep vein thrombosis and pneumonia were measured in each study group (Barmparas et
al., 2018).
Limitations of this study were significant, however, in that the sample size was
small, the initiation and discontinuation of cisatricurium was not based on a protocol, but
rather practice of the intensivists employed, and information was collected from a single
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institution. The researchers concluded that longer duration of neuromuscular blockade in
patients with ARDS may be necessary but higher quality studies are required.
In a single-center, retrospective cohort study, Merkel et al. (2019) set out to
determine proper administration of cisatricurium IV infusion in ARDS patients and
identify clinical elements that affect dosing. The data was obtained on 120 newly
intubated adults who had received cisatricurium. Of note, patients with ARDS of a less
severe category with a PaO2/FiO2 of less than 301 mmHg were employed for this
research. To ensure an adequate level of paralysis, TOF parameters were utilized to
capture patients which had documented 1/4 or 2/4 twitches. Institutional policies
recommended initial infusion rate of cisatricurium at 0.5-10 µg/kg/min and to increase
the drug by 25% per hour to obtain the prescribed number of twitches. A dose was
considered “stable” if two consecutive, desired TOF readings occurred on the same site
after at least three hours of infusion initiation. Thirty-nine patients met the stable dose
criteria and were used in the final analysis.
Ultimately, this small study determined that in order to achieve a TOF of 1/4 or
2/4 the median dose of cisatricurium was 2 µg/kg/min and that dosing requirements are
less in those with acute kidney injury (AKI). Unfortunately, surveys obtained displayed
50-60% of nurses measuring TOF are inconsistent, rendering the results less useful.
Additionally, a mortality rate of 56% was recorded, which is higher than the national
average of ARDS mortality and is likely due to the large percentage of
immunosuppressed patients studied. Due to these variables and the small sample size, this
study is clinically insignificant.

12

Combined Therapies
Management strategies for patients with ARDS largely surround the avoidance of
the development of ventilator-associated lung injury. Some of the selected studies had
used ECMO, neuromuscular blockade and prone therapy together. The lung-protective
methods of low volume, low pressure ventilator settings can be complicated by
hypercapnia and subsequent respiratory acidosis (Parekh et al., 2018). ECMO can
mitigate this issue by removing carbon dioxide from the blood. One reviewer writes that
proning the patient may be beneficial when combined with ECMO if it is safe and
feasible, however, prone positioning should be considered without ECMO first if low
volume, low pressure ventilator settings can be achieved (Parekh et al., 2018).
Prone position therapy and ECMO were combined in a retrospective, singlecenter analysis that focused on 12 patients diagnosed with ARDS. Patients had to be
ventilated for under 60 days before ECMO and prone positioning could be initiated.
Kipping et al. (2013) hypothesized that the facilitated alveolar recruitment from prone
positioning shared with the rest which ECMO provides the lungs would yield
improvement in oxygenation and reduce risk of acute lung injury. In the conclusion, the
researchers note these two therapies combined may improve oxygenation, however, the
study is small and the ECMO equipment studied is somewhat out of date. An interesting
and important feature extracted in this study is that ECMO and prone therapy were able
to occur simultaneously in all 12 patients without complications such as loss or
dislocation of intravascular catheters or endotracheal tubes (Kipping et al., 2013). These
findings offer encouragement for larger studies in the future.
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The combination of prone positioning and ECMO therapy were also observed in a
prospective study of 15 patients with severe ARDS (Guervilly et al., 2014). Adult
patients were proned if he/she demonstrated a PaO2/FiO2 was less than 70 mmHg, plateau
pressures of greater than 32 cmH20, or were unable to wean from ECMO after 10 days of
support. Participants were also heavily sedated and paralyzed with ciastracurium. Of the
15 patients, two had proned for two sessions and nine had proned for one session. The
median amount of time spent in the prone position was 12 hours. In conclusion,
oxygenation was greatly improved by prone positioning and may help to wean a patient
off ECMO. Limitations exist, however, such as the small sample size and delayed use of
proning. Of note, complications such as decannulation or accidental extubation did not
occur as a result of prone maneuvering.
Information and studies may be lacking overall to delve further into the
superiority of manual versus automatic proning. Otherwise, variables are highlighted in
prone therapy, neuromuscular blockade and ECMO therapy in the form of hospital LOS,
ICU LOS, discharge disposition, and complications. Combatting ARDS mortality rate
most effectively, however, is not yet determined based on these studies. Once comparison
of appropriate RCT’s is underway, the researcher aims to display conclusive evidence to
support one therapy over the other.
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Theoretical Framework
The utilization of a theory or concept framework in research is imperative for
creating logical sequence of interventions and documentation, understanding
relationships, and outlining shared beliefs and assumptions in a given profession
(McEwen & Wills, 2019). To appropriately capture the wide array of necessary elements
in systematic review of patients suffering with ARDS and the selected interventions, a
grand nursing theory based on human needs will provide guidance.
Virginia Henderson had an enormous impact in the 20th century as a nursing
educator, researcher, and visionary. Her holistic design accounted for the interventions a
nurse could provide in any given environment to facilitate the return of a patient’s
previous level of function and self-care. If devoted, nursing care cannot restore an
individual’s health, then the nurse will guide the patient into a dignified, peaceful death.
“Health was not explicitly defined, but it is taken to mean balance in all the realms of
human life” (McEwen & Wills, 2019, p. 137). Henderson’s Nursing Need Theory
describes for 14 activities for client assistance: breathe normally, eat and drink
adequately, eliminate body wastes, move and maintain desirable postures, sleep and rest,
maintain body temperature within normal range, keep the body clean and protect the skin,
avoid danger in the environment and avoid injuring others, communicate with others,
worship according to one’s faith, work in a way that creates a sense of accomplishment,
engage in various forms of recreation, and to attain normal development and health with
available facilities (McEwen & Wills, 2019). These activities encompass the four major
concepts of person, environment, health, and nursing.
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Henderson’s significant contribution to the field of nursing is undisputed. Her
works were imbedded in major nursing textbooks for 30 years. Each element in the 14
activities for client assistance can be framed as a research question and guide the
approach of the researcher. Additionally, the activities address all potential aspects of an
individual, from physiologic, psychologic, sociologic, spiritual, and moral. Thus, the
major concepts of Henderson’s theory can be applied to guide a variety of studies.
In a research study regarding ARDS and the interventions employed to combat
the multiple effects of ARDS, Virginia Henderson’s theory will serve as an effective
framework. Her chief focus further incorporates Maslow’s Hierarchy of Needs to the
nursing field. Utilization of the theorized basic needs will help shape the focus of
attention and discussion, with three of the physiologic categories particularly in mind:
breathe normally, move and maintain desirable postures and to sleep and rest. It is
important to consider these physiologic categories when treating patients with severe
ARDS, as these individuals are physiologically compromised, and the prescribed
treatments may increase the risk for each category’s degradation.
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Method
Purpose
The purpose of this study is to compare the best evidence regarding current
treatment options of prone therapy, neuromuscular blockade, and extracorporeal
membrane oxygenation (ECMO) therapy, in decreasing mortality rates for adult patients
with severe ARDS. Studies offer support and criticism of each therapy utilization to
maximize alveolar recruitment while simultaneously preventing acute lung injury. The
PICO approach was used to frame the research question that guides this study: Among
patients suffering with severe ARDS, which is more effective between prone therapy,
ECMO therapy and neuromuscular blockade in decreasing mortality rates?
Design
A systematic review was employed for this study, utilizing the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, to
ensure adequate integration of research evidence on the use of prone positioning,
neuromuscular blockade and ECMO as chief interventions to reduce mortality rates in
ARDS patients. Included in these guidelines is a 27-item checklist to capture the
minimum items required for reporting and a 4-phase flow diagram which depicts the
literature search strategy (Liberati et al., 2009). All guidelines were adhered to when
choosing appropriate studies to include in this systematic review. Framework adopted
from Virginia Henderson’s grand theory regarding the 14 activities for client assistance
will helped in creating an orderly flow of information. Specifically, three of the basic
human activities focus on physiologic characteristics that align with this project. The
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physiologic factors of interest are to breathe normally, move and maintain desirable
postures and to sleep and rest. Data collected from each study focused on these key
features and determine the impact of each treatment method for ARDS.
Inclusion/Exclusion Criteria
Inclusion criteria were randomized controlled trials (RCT) and meta-analyses in
English, conducted within the last ten years. All patients were in the ICU, intubated with
a diagnosis of ARDS. Additionally, treatment included prone positioning, use of
neuromuscular blockade and/or ECMO. Male and female patients were included.
Exclusion criteria were patients who were not diagnosed with ARDS, utilized ECMO or
paralytics in non- ARDS patients and individuals less than 18 years of age.
Search Strategy
To conduct a targeted search for the literature review Google Scholar, PubMed,
Cochrane library, and the CINAHL databases were used to find appropriate articles.
These search engines provided articles from the New England Journal of Medicine,
Mediators of Inflammation, Respiratory Care, the Journal of Clinical Medicine Research
and Cureus. Both the ancestry approach and keyword search with Boolean operators were
employed. Keywords utilized in this search included acute respiratory distress syndrome
(ARDS), ARDS physiology, prone therapy, neuromuscular blockade ARDS,
extracorporeal membrane oxygenation (ECMO) therapy, and ECMO therapy ARDS.
Each article was screened for the decided inclusion and exclusion criteria utilizing
the PRISMA flow diagram (see Figure 1). The goal of this review was to provide a
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summary of evidence on each component of the research problem and the most effective
treatment in reducing mortality in patient’s diagnosed with severe ARDS.
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Figure 1
Four-phase flow diagram for PRISMA (Liberati et al., 2009)

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n =19 )

Additional records identified
through other sources
(n = 4 )

Included

Eligibility

Screening

Records after duplicates removed
(n =21 )

Records screened
(n = 21 )

Records excluded
(n = 16 )

Full-text articles
assessed for eligibility
(n = 5 )

Full-text articles
excluded, with reasons
(n = 0 )

Studies included in
quantitative synthesis
(n = 5 )

Data Collection

Studies included in
quantitative synthesis
(meta-analysis)
(n = 5 )
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A summary table of the selected articles was created with pertinent information
about each study, including aim, type of study, design, population, methods, data
collection, determined level of evidence, data analysis, results/outcomes, and mortality
rate at day 28, 60, and 90. These specific time frames were observed in the reviewed
studies and incorporated in this systematic review. Included studies were also screened
for the seven specific elements from Virginia Henderson’s 14 activities of client
assistance and needs. The theorized basic needs are the focus of discussion for patients
who survive ARDS, with three of the physiologic categories particularly in mind: breathe
normally, move and maintain desirable postures and to sleep and rest.
Critical Appraisal
Critical appraisal of each article assisted in the extraction of the strengths and
weaknesses offered in each review. A guide to overall critique of a quantitative research
is provided by Polit and Beck (2017), which includes report title, abstract, problem
statement, hypothesis or question, literature review, framework, methods, results,
discussion, and general issues. Additionally, this research will adhere to the PRISMA
guidelines and each study will be appraised with the Critical Appraisal Skills Programme
(CASP) to ensure integrity of the analysis. Following individual study appraisal and
analysis a cross study analysis will be performed.
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Plan for Analysis
A systematic review requires the transformation of integrated quantitative data into
a comprehensive display of results. Collected data was entered into a cross analysis table
where it was organized by themes and patterns (Figure 2). With the data in such a form, it
aids in the comparison of pertinent outcomes for all studies under examination.
Figure 2.
Cross Analysis
Author,

Mortality Rate at Day:

Median Length of Stay

Year

(LOS) in Days
28

60

90

Intensive
Care Unit
(ICU)

Next, the results will be addressed.

Hospital
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Results
In order to select articles applicable for this systematic review, the PRISMA
checklist (Appendix A) and the PRISMA flowchart (Figure 1) were utilized. The original
search yielded 24 studies. After elimination of duplicate articles, 21 remained for further
review. Abstracts were then considered, and inclusion and exclusion criteria were
organized, which removed 16 more articles from this systematic review. The remaining
five, full text articles were considered in their entirety. Five total RCTs remained for
inclusion in this systematic review. Crucial elements were ordered in study collection
tables (Appendix B) and critically appraised using the CASP checklist (Appendix D).
The subsequent cross study analysis is displayed in the following section (Appendix E).
Neuromuscular Blockade
In a multicenter, double-blind trial, Papazian et al. (2010) (Appendix B 1) sought
to determine if an early introduction of neuromuscular blockade in ARDS patients would
improve clinical outcomes and mortality. Patients were selected between March 2006 to
March 2008 from 20 ICU’s in France. The subjects would have demonstrated acute
hypoxemic respiratory failure within 48 hours of endotracheal tube placement. Diagnosis
of ARDS was established if certain parameters were met, namely a PaO2/FiO2 (P:F) ratio
of less than 150 mmHg with a tidal volume of 6-8 milliliters (ml) per kilogram (kg) of
ideal body weight and a PEEP of at least 5 cmH2O. In addition, these patients had to have
demonstrated a lack of left atrial hypertension, captured either by a pulmonary wedge
pressure reading or on an echocardiogram. Originally, 1326 patients were examined for
eligibility. Once exclusion criteria were applied, 986 patients were removed from the
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trial. Reasons for exclusion were for age less than 18 years, pregnancy, lack of consent,
ongoing infusion of neuromuscular blockade during enrollment, increased intracranial
pressure, enrollment in another study within the previous month, severe, chronic disease
requiring ventilation at home, chronic and severe liver disease, actual body weight
exceeding 1kg per cm of height, chemotherapy-induced neutropenia, bone marrow
transplantation, time frame window missed, pneumothorax, and expected duration of
mechanical ventilation of less than 48 hours.
This trial ultimately secured a large host of 340 adult patients randomly divided
into two groups; 178 destined to receive cisatracurium besylate and 162 that were bound
to receive placebo administration, each for 48 hours. Several baseline characteristics of
the patients were illustrated. A few to note were that the cisatracurium group had a mean
age of 56 ± 16 and average P:F ratio of 106 ± 36. In the placebo group, the mean age
was 58 ± 15 and average P:F ratio of 115 ± 41. The primary endpoint observed was
patient death either before hospital discharge or within 90 days of enrollment. Secondary
outcomes were as follows: 28-day mortality, number of days without organ or system
failure between day 1 and day 28, number of days spent outside the ICU between days 128, rate of ICU acquired paresis, rate of barotrauma, number of ventilator free days
between days 1-28 and days 1-90, and MRC (Medical Research Council) scores on day
28 and on the day of ICU discharge. Hazard ratio was determined in the cisatracurium
compared to the placebo group for death at day 90 as 0.68 (95% confidence interval
[CI]). Crude 90-day mortality was also calculated to be 40.7% (95% CI) in the placebo
group and 31.6% (95%CI) in the cisatracurium group. Mortality at days 28 was 23.7%
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(95% CI) in the cisatracurium group and 33.3% (95% CI) among the placebo group
(Appendix C 1).
The author cited some limitations. Only cisatracurium was utilized and no other
neuromuscular blocking agent was studied. Additionally, the researchers tested the use of
this drug in early ARDS only and not in late ARDS. The conclusion of this study
demonstrated that early use of neuromuscular blockade (within 48 hours of ARDS
diagnosis) in ARDS patients with low tidal volume ventilation may improve clinical
outcomes. Low tidal volume ventilation refers to maintaining tidal volumes of 6-8
milliliters (ml) per kilogram (kg) of ideal body weight.
Critical analysis of the Papazian et al. (2010) study using the CASP checklist
(Appendix D 1) revealed a less precise treatment effect than desired. The cisatracurium
group had an absolute reduction of 9% in mortality at day 90 or discharge, however, the
study was ultimately underpowered. The sample size of this study was based on
comparisons to two earlier groups. Since the mortality of the placebo group in this study
was lower than that of the control group in earlier studies, this study was underpowered.
To account for this deficit, 855 patients would have been required to produce an 80%
statistical power.
In a multicenter, unblinded, randomized control trial, Moss et al. (2019)
(Appendix B 5) sought to determine the benefits of early administration of continuous
neuromuscular blockade in mechanically ventilated patients with moderate to severe
ARDS (ROSE trial). Moderate to severe ARDS was characterized in this study by a P:F
ratio of < 150 mmHg while on a PEEP of ≥ 8 cmH2O. Patients were randomly assigned
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in a 1:1 ratio to the intervention group or the control group. Both groups underwent low
tidal volume ventilation with PEEP of at least 8cm of water within two hours of
randomization. Patients would maintain the ventilator settings for up to five days. If the
patient demonstrated hypoxia, Pplat of greater than 30 cmH2O, hypotension, or a pH of <
7.15, the PEEP was allowed to be lowered. If selected for the intervention group, the
patient would have achieved deep sedation within four hours, followed by a 15mg bolus
of neuromuscular blockade (cisatracurium), then 37.5mg per hour continuous infusion of
cisatracurium for 48 hours. The control group would receive usual-care approach without
cisatracurium and with lighter sedation targets. Light sedation targets were measured by
the Richmond Agitation-Sedation Scale (RASS score 0 to -1), Riker Sedation-Agitation
Scale (3-4), or the Ramsay Sedation Scale (2-3).
The ROSE trial (2019) screened 4848 patients between January 2016 to April
2018 in 48 hospitals around the United States. Inclusion criteria included mechanically
ventilated patients with a P:F ratio of < 150 mmHg while on a PEEP of ≥ 8 cmH2O, noncardiac related respiratory failure, and bilateral opacities on chest x-ray/computer
tomography (CT) that ruled out pulmonary effusions, pneumothorax, or nodules. Patients
were excluded from the trial if the P:F ratio improved before enrollment or if the patient
had prior administration of neuromuscular blockade. Once inclusion and exclusion
criteria were applied, a total of 1006 patients remained for the study; 501 randomly
assigned to the cisatracurium group and 505 randomized to the control group. Prone
positioning and/or glucocorticoid administration were permitted as well.
The primary end point was death from any cause in the hospital at 90 days. In the
intervention group, 213 patients (42.5%) died within that period of time and 216 patients
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(42.8%) from the control group (P = 0.93). At the second interim anaylsis, this trial was
stopped for futility. Secondary end points compared the intervention group versus the
control group at day 28 regarding mortality (184 vs. 187), ventilator-free days (9.6 ± 10.4
vs. 9.9 ± 10.9), days out of the hospital (5.7 ± 7.8 vs. 5.9 ± 8.1) and days out of the ICU
(9.0 ± 9.4 vs. 9.4 ± 9.8), which displayed no statistical significant differences between the
two groups (Appendix C 5). Prone positioning and/or glucocorticoid administration were
utilized similarly in both groups.
This trial had both strengths and weaknesses, as well as limitations. One strength
was the strong staff compliance with the protocol, which aided in consistent ventilator
strategies used. This was also a large multicenter study and the subjects were randomized
to study groups. The trial was not blinded to the healthcare professionals. Another
weakness is that the ROSE trial was stopped early for futility, which renders it an
underpowered study. Traditional measurement of neuromuscular blockade with the TOF
measurements was not utilized in this study. Lastly, it is noted that the uncontrolled use
of prone positioning may have falsely affected the mortality rate.
Critical appraisal of the ROSE trial revealed a specific focus in the study and that
all the patients were randomized. The participants were all accounted for, baseline
characteristics were similar in both groups, and aside from the designated experimental
intervention, both groups were treated equally. This was not a blinded trial. With regard
to the treatment effect, at day 90, any cause of in-hospital death occurred in 213 patients
(42.5%) in the cisatracurium group and 216 patients (42.8%) in the control group (P =
0.93). Also, at a two-sides alpha level of 0.05, it was calculated that 1408 patients would
be needed in order for the trial to have 90% statistical power. Researchers were able to
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include 1006 patients, however, by the second interim analysis, the trial was stopped for
futility.
Venovenous ECMO
Peek et al. (2010) created a multicenter, randomized controlled trial with two
arms in order to determine the efficacy of conventional ventilation support versus ECMO
for severe adult respiratory failure (CESAR trial) (Appendix B 2). If entered into the
ECMO arm, the individual was transferred to an ECMO specialist center (not transferred
on ECMO). If the patient was hemodynamically stable, a standard protocol was applied,
including pressure restricted mechanical ventilation, and use of PEEP and FiO2 to
maintain oxygen saturation to greater than 90%, use of diuretics, and prone positioning.
After 12 hours, if patient did not positively respond to treatment with proof of maintained
oxygen saturation and/or pH measurement of less than 7.2, cannulation for ECMO was
placed. Once ECMO was utilized, it was conducted in the veno-venous mode and was
continued until lung recovery or apparent irreversible multiorgan failure ensued. Patients
entered into the conventional management (CM) would receive continuous conventional
ventilation, typically on a pressure control mode, with low-volume low-pressure
ventilation.
Patients were enrolled from 68 different centers in the United Kingdom (UK)
from 2001 to 2006. In this study, the severity of ARDS was measured with the Murray
scoring system, which considers four criteria that lead to the development of ARDS;
hypoxemia, respiratory system compliance, chest radiographic impression, and level of
PEEP (Raghavendran & Napolitano, 2011). Patients score from 0-4, with 4 rating as the
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most severe form of ARDS. In the beginning, 766 patients from 148 centers were eligible
for consideration. To be included in the trial, patients required a Murray score of three or
more or a pH of less than 7.2 and uncompensated hypercapnia despite ideal ventilator
use. Additionally, all patients in the trial were between the ages of 18-65. Patients were
excluded if FiO2 was set greater than 80% or peak pressure was greater than 30 cmH2O
for seven days. Patients were also excluded for signs of intracranial bleeding, if there
were contraindications for heparin administration, or if any contraindications existed for
continuation of active treatment. Ventilator settings were assessed on an hourly basis.
One hundred eighty patients from 68 centers met the inclusion criteria and were
entered into the CESAR trial. Ninety patients were randomized to conventional ventilator
support and the remaining 90 were randomized to receive ECMO treatment. The baseline
characteristics between the two groups were similar with a leading cause for ARDS being
pneumonia in approximately 2/3 of the total patients. Some that were elected to
participate in the ECMO group did not ultimately receive ECMO therapy. Following
standardized treatment of ARDS patients, which was to occur prior to ECMO therapy, 17
patients no longer qualified for ECMO. Five other patients died before or during transport
to the designated ECMO center. Mean Murray scores between the ECMO group that
received therapy, the ECMO group that did not, and control (CM) group were 3.4 ± 0.3,
3.6 ± 1.3, and 3.4 ± 0.3, respectively.
The primary end point in this trial was survival at 6 months without severe
disability. Note that severe disability was defined as confinement to a bed and no longer
able to wash or dress alone. Severe disability No death or severe disability was observed
in 57 patients in the ECMO group and 41 in the CM group, creating a relative risk of 0.69
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(95%CI 0.05 to 0.97) with p = 0.03. This finding is statistically significant. The study is
missing information on three patients. Fifty-seven patients in the ECMO arm died in less
than 6 months or died before discharge and 45 in the CM arm. This created a relative risk
of 0.73 (95%CI 0.52-1.04) with a p = 0.07. This finding was not statistically significant.
Secondary outcomes consisted of ECMO patients who were proned (4%) versus patients
in the CM (42%) with a p = 0.58. Another secondary outcome considered was median
ICU days in both the ECMO and the CM arm, which was 24 ICU days versus 13 ICU
days, respectively. Median hospital days in each group was 35 in ECMO arm and 17 CM
arm. (Appendix C 2). Strengths and weaknesses are also noted. Ultimately, this study
provided evidence that patients that fit the inclusion criteria who fail optimal
conventional ventilator management should be transferred to an ECMO specialist center
for ECMO treatment to decrease the likeliness of death or severe disability.
Critical appraisal of the CESAR trial (Peek et al., 2010) (Appendix D 2) revealed
the original power calculations were based on anticipated 70% mortality prediction in the
control group. The researchers considered a 10% chance of severe disability in both arms
and determined 240 total patients were required. Sample size review conducted in 2003
revealed only 60% of target size was attained. It was agreed that a lower sample size of
180 patients would be enough to detect a reduction by 1/3. Mortality in the ECMO arm
was lower than the conventional arm, however it did not reach statistical significance.
In the Combes et al. (2018) (Appendix B 4) international, multicenter randomized
control trial, researchers sought to determine the efficacy of venovenous ECMO in
patients with severe ARDS (EOLIA trial). Patients were determined to have severe
ARDS if, under the conditions outlined by the American-European Consensus
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Conference (Bernard et al., 1994), one of the three following criteria were met; an arterial
blood pH of less than 7.25 with a partial pressure of carbon dioxide of at least 60 mmHg
for over six hours, a P:F ratio of less than 50 mmHg for more than 3 hours, or a P:F ratio
of less than 80 for more than six hours. Randomization was stratified according to the
duration of ventilation before randomization and according to the center in which the
patients were being treated. A centralized, web-based randomization system ensured
concealment of patient assignments. Exclusion criteria applied if the patient was
ventilated more than 7 days, if the subject was less than 18 years old, had a body mass
index (BMI) over 45, cardiac failure resulting in ECMO, long term respiratory
insufficiency, history of heparin induced thrombocytopenia, life expectancy less than five
years due to cancer, a Simplified Acute Physiology Score (SAPSII) (Le Gall, 1993) of
more than 90, cardiac arrest resulting in coma, irreversible neurologic injury, expected
difficulty obtaining vascular access for ECMO, or the withdrawal of life sustaining
treatment.
Enrolled patients were all intubated via endotracheal tube for less than 7 days.
Patients randomized to the venovenous ECMO group would have percutaneous cannulas
placed and adjustments made via the ECMO device to maintain a PaO2 between 65-90
mmHg, an arterial oxygen saturation (SaO2) of greater than 90%, and a PaCO2 of less
than 45 mmHg. Mechanical vantilation during ECMO was set to an FiO2 of 30-50%, a
PEEP of 10 cmH2O, respiratory rate of 10-30 breaths per minute, and a tidal volume
adjusted to maintain a plateau pressure (Pplat) of 24 cmH2O or less (high pressure level
of 24 cmH2O or less if in bilevel positive airway pressure-release ventilator mode). An
anticoagulation target APTT of 40-55 or anti Xa of 0.2-0.3 with heparin was
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implemented as well. Patients in the control group were on a volume-assist-controlled
ventilation with an FiO2 set to obtain an SaO2 between 88-95% and a of 55-80 PaO2
mmHg, PEEP set to ensure a Pplat not to exceed 28-30 cmH2O, tidal volume set to 6 ml
per kg of ideal body weight, and respiratory rate set as high as 35 breaths per min. It was
strongly encouraged to utilize neuromuscular blockade and prone positioning in this
group. Sodium bicarbonate infusions and predetermined ventilator adjustments could be
made to ensure target goals in the individual’s pH, PaCO2, and Pplat. Cross over from
control to ECMO was possible if the patient maintained a SaO2 of less than 80% over 6
hours.
The EOLIA trial evaluated 1015 patients for eligibility with an aim for a target
sample of 331 individuals. After the fourth interim analysis, the data safety monitoring
board (DSMB) recommended to stop the trial after only 249 patients, according to the
preset futility stopping rules. It was determined that this trial was unlikely to reach a
definitive result. The ECMO group had 124 patients and the control group had 125
patients. This study was executed in 64 centers, mostly across France, and included some
ECMO centers and some non-ECMO centers. The non-ECMO centers were to have
extensive practice in treating ARDS patients as well as the ability to establish ECMO
treatment within two hours of randomization.
The primary end point measured was mortality at 60 days, which displayed
44/124 (35%) from the ECMO group and 57/125 (46%) from the control group. No
significant statistical difference is noted, with a relative risk of 0.76 (95% CI, 0.55-1.04)
and P value of 0.09. Secondary endpoints when comparing the ECMO group to the
control group, consist of a lower relative risk of treatment failure 0.62 (95% CI, 0.47 to
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0.82; P < 0.001), which was death by day 60, more days spent without prone positioning
(59 vs. 46 days), and more without renal replacement therapy (50 vs. 32 days).
Additionally, the ECMO group spent more days than the control group free of cardiac
failure and renal failure. Less patients from the ECMO group versus the control group
required the other available interventions such as prone positioning, recruitment
maneuvers, inhaled nitric oxide or prostacyclin, or glucocorticoids. However, more
patients in the ECMO group , suffered significantly more bleeding events than that of the
control group (46% vs. 28%), higher rates of severe thrombocytopenia (27% vs. 16%),
and fewer cases of ischemic stroke (Appendix C 4).
Limitations, strengths and weaknesses were identified. One limitation was that the
trial was stopped short of the calculated sample size by 82 patients, which only secured
75% of their goal. The sample size was halted due to predetermined restrictions set in
place based on futility. A definitive result based on this trial was unlikely. Another
limitation was that 28% of patients crossed over from the control group to the ECMO
group, which created an inadequate picture of the ECMO data results. A strength
presented in the EOLIA trial was that it is the largest multicenter ECMO study to be
conducted since the CESAR trial . Additional strengths include the use of standardized
criteria and protocols which enabled consistent treatments in both ECMO management
and ventilator strategies. The criteria utilized by the researchers also ensured that 98% of
patients selected for the ECMO arm did receive ECMO therapy. One weakness identified
was that this trial included individuals treated at ECMO and non-ECMO centers.
Additionally, the trial was underpowered to detect mortality.
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Critical analysis of the EOLIA trial (Appendix D 4) reveals that the trial did focus
on a particular intervention, patients were randomized for the trial, and all patients were
properly accounted for. Medical and nursing staff were not blinded however, research
staff members were blinded. Baseline characteristics of each group were similar. Patients
who received ECMO were treated in ECMO and non-ECMO institutions. With regard to
the treatment effect, at day 60, mortality in the ECMO group was 35% compared to 46%
in the control group. Sixty-day mortality was not significantly lower in the ECMO group.
The estimated treatment effect measured at an alpha level of 5% and with groupsequential analysis after randomization of 60 patients, the maximum sample would have
needed to be 331 to have an 80% power. At the fourth planned sequential interim
analysis, the trial was stopped in accordance with prespecified rules, leaving 249 patients
in the trial. Results can be applied to local populations and all clinically important
outcomes were considered. In conclusion, the benefits of ECMO did not outweigh the
harms and costs.
Prone Positioning
A multicenter, prospective, randomized control trial (Guérin et al., 2013) was
created to determine the outcomes of early application of prone positioning in patients
with severe ARDS (PROSEVA trial) (Appendix B 3). Researchers in this study defined
severe ARDS consistently with American-European Consensus Conference criteria
(Bernard et al., 1994) which requires a patient to display a P:F ratio of < 150 mm Hg,
with an FiO2 of ≥ 0.6, a PEEP of ≥ 5 cmH2O, and a tidal volume of about 6 ml per
kilogram of predicted body weight. These patients were randomized via the use of a
centralized Web-based management system to be in the prone or supine group after 12-24
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hours of observation and stabilization. Patients in the supine group were in a semirecumbent position and physiologic measurements were assessed every six hours. Those
randomized to the prone group were turned to the prone position for ³ to 16 hours. This
intervention was repeated for ≥ to 28 days. Prone positioning was ceased if the P:F ratio
was ≥ 150mmHg with a PEEP £ 10 cm H2O and FiO2 £ 60% for ³ 4 hours after the prior
prone positioning, complications during prone positioning, or decreased P:F ratio before
two consecutive prone sessions. Note that mechanical ventilation was modeled after
ARDSnet (n.d.) low tidal volume protocol, with a goal pH of 7.20-7.45 and end
inspiratory plateau pressure goal £ 30.
The PROSEVA trial enrolled patients between 2008-2011 from 26 ICUs in
France and one in Spain. To be included in the study, patients must display a P:F ratio of
< 150 mm Hg, with an FiO2 of ≥ 0.6, a PEEP of ≥ 5 cmH2O, and a tidal volume of about
6 ml per kilogram of predicted body weight. These patients also had an endotracheal tube
in place and mechanically ventilated for less than 36 hours. Reasons for exclusion were
intracranial pressure of > 30mmHG, cerebral perfusion pressure < 60mmHg, a mean
arterial pressure of > 65mmHg, massive hemoptysis, recent tracheal surgery, facial
trauma, recent permanent pacemaker placement, recent deep vein thrombosis, unstable
fractures of spine, pelvis, or femur, lung transplant, pregnancy, large body surface area
burns, anterior chest tube with air leak, diseases resulting in life expectancy less than one
year, end-of-life decision, prone positioning prior to inclusion, or nitric oxide, almitrine
bismesylate, or ECMO therapy.
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Guérin et al. (2013) was able to secure 466 patients total, with randomization
resulting in 229 in the supine group and 237 in the prone group. Baseline characteristics
between the two groups were similar. The prone group was 70% male with a mean age of
58 ± 16. The supine group was 66.4% male with a mean age of 60±16. Those with sepsis
in the prone group were 82.2% and 85.2% in the supine group (p < 0.05). Additional
interventions for consideration were vasopressors (prone 72.6% and supine 83%, p <
0.05), neuromuscular blockade (prone 91% and supine 82.3%, p < 0.05), continuous renal
replacement mean of 17.1% and mean use of glucocorticoids at 44.9%.
Primary end point was 28-day mortality, with prone group averaging 16% and the
supine group at 32.8% (p < 0.001). Secondary outcomes in supine vs. prone were
mortality from any cause at 90 days (41% vs. 23.6%, 95%CI 0.29-0.67, p < 0.001),
successful extubation at 90 days (65% vs. 80.5%, 95%CI 0.29-0.70, p < 0.001), time to
successful extubation in survivors (19 vs. 17 days, p = 0.87), time to successful
extubation in non-survivors (16 vs. 18 days), ventilator-free days at day 28 (10 vs. 14, p <
0.001), ventilator-free at day 90 (43 vs. 57, p < 0.001), pneumothorax (5.7% vs. 6.3%,
95%CI 0.39-2.02, p = 0.85), noninvasive ventilation at 28 days (4.7% vs. 1.8%, 95%CI
0.27-1.86, p = 0.37), and noninvasive ventilation at 90 days (8.1% vs. 6.4%, 95% CI
0.36-1.67, p = 0.59) (Appendix C 3). Some strengths to note were that the researchers had
an appropriate power calculation and that the ventilation strategy, including the weaning
strategy, was standardized with a table to determine PEEP and FiO2. One weakness in this
study was that all of the centers selected had greater than five years of experience in
proning patients, therefore the success of this intervention may not be applicable to all
institutions. Another weakness was the difference in baseline characteristics between the
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two groups, namely the SOFA score, use of vasopressors, and use of neuromuscular
blockade.
Critical analysis of the PROSEVA trial (Guérin et al., 2013) (Appendix D 3)
displayed the prone group had a 51% relative reduction and 17% absolute reduction in
28-day mortality compared to the supine group. Additionally, the power calculation was
appropriate, with an estimated sample of 456 patients would generate a 90% power to
detect an absolute reduction of 15 percentage points with prone positioning. Referring to
the baseline characteristics of the two groups, all were fairly even. Ultimately, the
benefits outweigh the harms and costs, and early and long sessions of prone positioning is
considered to improve mortality in patients with severe ARDS.
Next, summary and conclusions will be addressed.
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Summary and Conclusions
Acute Respiratory Distress Syndrome is a major concern in hospitals and carries a
reported mortality rate of approximately 40-50% with up to 150,000 cases diagnosed in
the United States annually (El-Haddad et al., 2017). Councils have been formed to
accurately measure the severity of ARDS, most notably the American-European
Consensus Conference, which outlined criteria to categorize a patient with mild to severe
ARDS and a standardized definition facilitated the conduct of ARDS research.
Interventions and therapies have been studied on a large scale to determine the best, most
consistent method to decrease morbidity and mortality rates in this population. This
systematic review focused on randomized control trials (RCT), evaluating three widely
used interventions for severe ARDS including prone positioning for improved oxygen
recruitment, resting the pulmonary system with venovascular ECMO support, and
sedating with a neuromuscular blockade.
This systematic review was intended to examine which intervention, between
prone positioning, ECMO, or neuromuscular blockade, decreases mortality rates most
reliably among patients with severe ARDS. In many studies, multiple interventions were
used simultaneously. A comprehensive search was done using Google Scholar, PubMed,
Cochrane library, and the CINAHL databases to find appropriate articles. To ensure a
methodical selection of studies, the PRISMA checklist (Appendix A) and the four-phase
diagram (Figure 1) were utilized. After careful examination of various journal articles,
five randomized control trials were selected for this systematic review. In order to
organize the data available in each trial, study collection data and outcome data collection
were constructed to extract and tabulate applicable information (Appendices B1- B5 and
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C1- C5). In order to critique each study and apply the evidence to this systematic review
and the Critical Appraisal Skills Programme (CASP) checklist was utilized (Appendices
D1- D5). Finally, the key findings were reduced to a cross analysis table for comparison
to satisfy the primary objectives of this review (Appendix E). The primary objectives
obtained regarded mortality rate at days 28, 60 and 90 and length of stay (LOS) in the
intensive care unit (ICU) and in the hospital overall.
In the cross analysis (Appendix E), comparisons of the selected trials were made.
The RCTs that failed to decrease ARDS mortality rates across all time periods were
Combes et al. (2018) in the EOLIA trial and Moss et al. (2019) in the ROSE trial.
Mortality at day 28 in the intervention group versus the control group were measured in
the Papazian et al. (2010) to be 23.7% versus 33.3% with a P value of 0.05, in the Guérin
et al. (2013) to be 16% and 32.8% with a P value of < 0.001, and in Moss et al. (2019) to
be 36.7% and 37%. Prone positioning demonstrated the greatest decrease in mortality rate
at day-28 among the included studies. At day 60, mortality was measured in the
intervention group versus the control group in Guérin et al. (2013) to be 23.6% and 41%
with a P value < 0.001 and Combes et al. (2018) as 35% versus 46% with a P < 0.09.
Prone positioning, again, demonstrated a greater decrease in mortality rate at day-60 in
those that reported such findings. At day 90, mortality was measured between the
intervention group and control group in Combes et al. (2018) to be 37% versus 47% and
in Moss et al. (2019) as 213 (42.5 ± 2.2) versus 216 (42.8 ± 2.2) with a P value of 0.93.
Between the two studies which measured mortality rate at day-90, there was no
significant difference. Length of stay (LOS) in the ICU was calculated as median days in
the intervention versus control group in Peek et al. (2010) as 24 versus 13, in Guérin et al.
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(2013) to be 24 ± 22 versus 26 ± 27 with a reported P value of 0.05, and in Combes et al.
(2018) to be 23 versus 18. In regard to hospital LOS between the intervention group and
control group, which was reported in only two of the studies, in Peek et al. (2010) was 35
versus 17 median days and in Combes et al. (2018) to be 36 versus 18 median days. Peek
et al. (2010) demonstrated the shortest median length of stay in the ICU in the control
group and was almost identical with Combes et al. (2018) on median length of stay in the
control group in the hospital.
Adverse events were considered and recorded in each trial as well. Every patient
in the selected RCTs in this systematic review were intubated via endotracheal tube and
on mechanical ventilation. Additionally, all of the patients included satisfied the
American-European Consensus Conference definition or the Murray scoring system for
severe ARDS. Ventilator setting choices followed the current standard of care guidelines
for ARDS, primarily aiming for low volume and low pressure. Subsequently, similar
adverse events were reported in each study, for example ventilator-associated pneumonia
(VAP), barotrauma, pneumothorax, as well as successful time to extubation, and
noninvasive ventilation. All studies proved to have comparable results. The ACURASYS
trial displayed greater incidences of barotrauma and pneumothorax in the control group
compared to the other studies. Additionally, the two ECMO trials did not include
barotrauma and pneumothorax complication data to compare. Additional adverse events
included thrombocytopenia, pneumonia, cardiovascular events, bleeding, various types of
strokes, hypothermia, and multiorgan failure. Bleeding was a significant risk in the
CESAR and EOLIA trials, as ECMO therapy utilizes large bore vascular canulation
systems and anticoagulants. Paresis and weakness acquired in the ICU measured highest
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in the ACURASYS and ROSE trials due to the use of neuromuscular blockade in each
intervention group. The ROSE trial, however, had fewer events of paresis/weakness,
likely due to the lighter sedation targets included in the protocol utilized.
Across the included RCT’s, additional ARDS interventions were combined. Prone
positioning was included in all of the studies as an adjunct therapy, except in Guérin et al.
(2013) as it was the primary intervention used. Combes et al. (2018) in the latest ECMO
study and Moss et al. (2019) in the most recent neuromuscular blockade trial were unable
to determine whether or not prone positioning played a role in some of the positive
outcomes measured. A shared ARDS intervention was the use of neuromuscular blockade
in the PROSEVA trial, which did not exclusively discuss its relevance in mortality rate
outcomes. In both the ACURASYS and ROSE trial, cisatracurium was the drug of choice
for neuromuscular blockade and neither trial utilized the TOF method to monitor level of
paralysis.
This systematic review identified several study limitations. First, only five studies
existed which met the inclusion and exclusion criteria. More RCTs of each intervention,
between ECMO, prone positioning, and neuromuscular blockade would have built a
stronger review and created greater generalizability. Additionally, in each study,
differences in mortality rate end points was a barrier to reliably compare interventions to
identify efficacy to reduce overall mortality. Such variations included a 28, 60, and 90
day mortality rate end point, which was not measured in every study. Peek et al. (2010)
chose the most atypical end point of death or severe disability at six months or less.
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Conclusions drawn from this systematic review are the ACURASYS trial was
underpowered, the CESAR trial displayed a decrease in mortality in the ECMO arm but
did not reach statistical significance, and both the EOLIA trial and the ROSE trial were
stopped for futility. Prone positioning (Guérin et al., 2013) showed the greatest decrease
in mortality overall and reached statistical significance. The findings from this systematic
review may assist providers and caregivers working in the ICU to choose the most
appropriate, beneficial intervention to treat patients with ARDS. This comprehensive
review evaluated pertinent findings regarding the use of prone positioning,
neuromuscular blockade, and ECMO therapy will inform healthcare organizations to
provide the right equipment and technology to implement the intervention most likely to
decrease mortality. Moreover, if evidence-based interventions are selected, it may lead to
fewer days spent in the ICU, and lower costs and improved quality of life for patients
status post severe ARDS.
With regard to Virginia Henderson’s Nursing Need Theory, it was difficult to
account for all of the physiologic categories in each study; breathe normally, move and
maintain desirable postures and sleep and rest. Utilization of the theorized basic needs
were intended to help shape the focus of attention and discussion. Although it is
important to consider these physiologic categories when treating patients with severe
ARDS, as these individuals are physiologically compromised, attention was not
exclusively dedicated to each of these patient needs and, thus, was not able to be
incorporated into a cross study analysis table for direct comparison.
Recommendations and implications for advanced nursing practice will be
discussed next
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Recommendations and Implications for Advanced Nursing Practice
Acute respiratory distress syndrome (ARDS) is a severe complication which
affects thousands of patients every year and is consequently responsible for high
mortality rates and increased healthcare costs. As the role of advanced practice registered
nurses (APRN) continues to grow, it is imperative for practitioners to remain current and
up to date on evidence-based practice and emerging new knowledge. This systematic
review was able to evaluate the most recent RCTs on ARDS interventions, compare their
efficiency and explore methods with inquiry in large trials. The APRN should be aware
of the limited generalizability of the studies and lack of randomized control trials (RCTs)
to date. Overall, this systematic review provides the APRN with relevant information to
inform decision-making when caring for patients with severe ARDS.
Upon conclusion of this systematic review, some recommendations can be made.
Prone positioning (Guérin et al., 2013) best demonstrates a decrease in mortality of adult
patients with severe ARDS when applied early and for extended intervals of time. The
use of ECMO and neuromuscular blockade cannot be completely excluded from
treatment, however, further studies are required to fully understand and develop a
standard of care for such interventions into regular practice. The APRN, in collaboration
with the critical care team, can consider the use of these alternate interventions if prone
positioning is contraindicated or not improving patient outcomes.
In considering the treatment options available to patients with severe ARDS, the
APRN may consider the secondary outcomes included in this systematic review. Patients
who are on a ventilator via endotracheal tube are at risk for an array of adverse events if
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mechanical ventilation settings are not carefully chosen and monitored. Examples of such
adverse events consist of barotrauma, pneumothorax, ventilator-associated pneumonia
(VAP), increased length of stay (LOS) in the ICU, increased LOS in the hospital,
extended periods of time on the ventilator, and disturbances in serum pH. The studies
report additional secondary outcomes the APRN may consider specific to each treatment
option. For example, in patients that receive ECMO, careful consideration of bleeding
and exsanguination will be weighed in the decision to initiate therapy. The APRN must
also consider that specific neuromuscular blockade study drugs may increase the risk of
paresis, paralysis, and weakness in some patients.
The study of adults with severe ARDS and methods to decrease the notable
mortality rate will continue. An APRN with the foundational knowledge provided in this
systematic review will prove to be essential in the pursuit of further RCTs. Proper
definition of preset protocols, standardized ventilator settings, inclusion/exclusion
criteria, and use of selected severs ARDS interventions will help to create stronger trials
in the future and thus, contribute to the development of evidence-based practice to
support improved outcomes for adults with severe ARDS.
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Appendix B
Table B 1
Study Collection Data
Papazian, L., Forel, J., Gacouin, A., Penot-Ragon, C., Perrin, G., Loundou, A., . . . Roch, A. (2010). Neuromuscular Blockers in
Early Acute Respiratory Distress Syndrome. New England Journal of Medicine, 363(12), 1107-1116. doi:10.1056/nejmoa1005372
Aim
Clinical outcomes
after 2 days of
therapy with
neuromuscular
blocking agents in
patients with early,
severe acute
respiratory distress
syndrome (ARDS).

Design
Multicenter,
double-blind
randomized
controlled trial
Cisatracurium
besylate group

Site
20
ICUs
in
France

Sample
340 adult patients
presenting to the ICU
with an onset of severe
ARDS within the
previous 48 hours.
178 in cisatracurium
besylate group

Placebo group
162 in placebo group

Method
Randomly
assigned
patients in a
1:1 ratio with
severe ARDS
to receive
cisatracurium
besylate or a
placebo for
48 hours.

Outcome
Primary outcome was death before hospital
discharge or within 90 days of enrollment.
Secondary outcomes were 28-day mortality,
number of days outside the ICU between
days 1-28 and days 1- 90, number of days
without organ failure between days 1- 28,
rate of barotrauma, rate of ICU-acquired
paresis, the MRC scores on day 28 and at the
time of ICU discharge, and numbers of
ventilator-free days between days 1-28 and
days 1- 90.

Note. Severe ARDS was defined as a ratio of the partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2)
of less than 150, with a positive end-expiratory pressure of 5 cm or more of water and a tidal volume of 6 to 8 ml per kilogram of
predicted body weight.

53

Table B 2
Study Collection Data
Peek, G., Elbourne, D., Mugford, M., Tiruvoipati, R., Wilson, A., Allen, E., . . . Truesdale, A. (2010). Randomised controlled trial
and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult
respiratory failure (CESAR). Health Technology Assessment, 14(35). doi:10.3310/hta14350
Aim
To compare
efficacy and costeffectiveness of
conventional
ventilatory support
versus
extracorporeal
membrane
oxygenation
(ECMO) for severe
adult respiratory
failure.

Design
Multicenter,
randomized
controlled
trial with
two arms.

Site
Glenfield
Hospital’s
ECMO
center,
Leicester,
and approved
conventional
treatment
centers and
hospitals
within the
UK.

Sample
180 patients, aged 18–
65 years, with severe,
respiratory failure,
defined as a Murray
lung injury score ≥ 3.0,
or uncompensated
hypercapnia with a pH
< 7.20 despite optimal
conventional treatment.
90 in ECMO arm

Method
Participants
were
randomized
to
conventional
management
(CM) or to
consideration
of ECMO.

Outcome
Primary outcome measured was death
or severe disability at 6 months.
Secondary outcomes included duration
of ventilation, use of high
frequency/oscillation/jet ventilation,
use of nitric oxide, prone positioning,
use of steroids, length of ICU stay,
and length of hospital stay. For ECMO
patients only, mode (venovenous/
veno-arterial), duration of ECMO,
blood flow and sweep flow

90 in CM arm
Note. The Murray scoring system regards 4 criteria to determine presence of ALI/ARDS: hypoxemia, respiratory compliance, chest
radiographic impressions, and level of PEEP. Each category is scored from 0 to 4. A score of zero indicates no lung injury, a score of
1 – 2.5 is indicative of mild to moderate lung injury, and an ultimate score of more than 2.5 indicates the presence of ARDS.
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Table B 3
Study Collection Data
Guérin, C., Reignier, J., Richard, J.-C., Beuret, P., Gacouin, A., Boulain, T., … Ayzac, L. (2013). Prone Positioning in Severe Acute
Respiratory Distress Syndrome. New England Journal of Medicine, 368(23), 2159–2168. doi: 10.1056/nejmoa1214103
Aim
Evaluation
of the
early
application
of prone
positioning
on
outcomes.

Design
Multicenter,
prospective,
randomized
control trial

Site
Selected
from 26
ICU’s in
France and 1
in Spain.

Sample
466 adult patients with
severe acute
respiratory distress
syndrome (ARDS) and
intubated for less than
36 hours.

All sites
noted for
229 in supine group
daily practice
in prone
237 in prone group
positioning
for at least 5
years.

Method
Random assignment of
466 patients with severe
ARDS to undergo
prone-positioning
sessions of at least 16
hours or to be left in the
supine position.
Randomization was
computer-generated and
stratified according to
ICU.

Outcome
Primary end point was 28-day
mortality.
Secondary end points were 90-day
mortality, rate and time of successful
extubation, length of stay in the ICU,
complications, use of noninvasive
ventilation, tracheotomy rate, number
of days free from organ dysfunction,
ventilator settings, measurements of
arterial blood gases, and respiratory
system mechanics during the first
week following randomization.

Note. Severe ARDS was defined as a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Fio2) of less
than 150 mm Hg, with an Fio2 of at least 0.6, a positive end-expiratory pressure of at least 5 cm of water, and a tidal volume close to 6
ml per kilogram of predicted body weight.
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Table B 4
Study Collection Data
Combes, A., Hajage, D., Capellier, G., Demoule, A., Lavoué, S., Guervilly, C., . . . Mercat, A. (2018). Extracorporeal Membrane
Oxygenation for Severe Acute Respiratory Distress Syndrome. New England Journal of Medicine, 378(21), 1965-1975.
doi:10.1056/nejmoa1800385
Aim

Design
Site
To
International, Centers in 16 different
determine randomized
countries.
efficacy
trial
of
Conducted largely in
extracorpo Extracorpore France by the Direction
real
al membrane de la Recherche Clinique
membrane oxygenation et du Développement,
oxygenati (ECMO)
Assistance Publique
on for
group
Hôpitaux de Paris.
severe
respirator Control
International centers that
y distress group
enrolled patients outside
syndrome
France were the legal
(ADRS).
sponsor for the trial in
their own country.

Sample
249 adult patients
who were intubated
for less than 7 days
that met the
American-European
Consensus
Conference
definition for
ARDS.
124 in ECMO group
125 in control group

Method
Randomly assigned
patients with severe
ARDS to receive
immediate venovenous
ECMO (ECMO group)
or continued
conventional treatment
(control group).
Crossover to ECMO
potential for patients in
the control group with
refractory hypoxemia.

Outcome
Primary end point was 60day mortality.
Secondary end point was
treatment failure (crossover
to ECMO or death in patients
in the control group and as
death in patients in the
ECMO group). Additional
end points were mortality at
other times, the time to death
until day 60, and an analysis
in which mortality was
compared in patients who
received ECMO and those
who did not.

Note. Severe ARDS defined by one of three criteria: a ratio of partial pressure of arterial oxygen (Pao2) to the fraction of inspired
Table B 5
oxygen (Fio2) of less than 50 mm Hg for more than 3 hours; a Pao:Fio2 of less than 80 mm Hg for more than 6 hours; or an arterial
blood pH of less than 7.25 with a partial pressure of arterial carbon dioxide of at least 60 mm Hg for more than 6 hours.
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Table B 5

Study Collection Data
Moss, M., Huang, D. T., Brower, R. G., Ferguson, N. D., Ginde, A. A., Gong, M. N., . . . Talmor, D. (2019). Early Neuromuscular Blockade
in the Acute Respiratory Distress Syndrome. New England Journal of Medicine, 380(21), 1997-2008. doi:10.1056/nejmoa1901686
Aim
Evaluate early
and continuous
application of
neuromuscular
blockade in
patients with
moderate to
severe acute
respiratory
distress syndrome
(ARDS) who are
also receiving a
high PEEP
strategy on the
ventilator.

Design
Multicenter,
unblinded,
parallelgroup,
randomized,
controlled
trial

Site
48
hospitals
in the
United
States

Sample
Adult patients undergoing mechanical
ventilation with following criteria for less
than 48 hours: Pao2:Fio2 of less than 150
mm Hg with a PEEP of 8 cm or greater of
water; bilateral pulmonary opacities on
chest x-ray or on CT that could not be
explained by effusions, pulmonary
collapse, or nodules; and respiratory
failure that could not be explained by
cardiac failure or fluid overload.
501 in early NMB with cisatracurium
group
505 in usual care group

Method
Randomly assigned
1006 patients to a 48hour continuous
infusion of
cisatracurium with
concomitant deep
sedation (intervention
group) or to a usualcare approach
without routine
neuromuscular
blockade and with
lighter sedation
targets (control
group).

Outcome
Primary outcome was inhospital death at day 90.
Secondary outcomes
were organ dysfunction
(as determined by the
SOFA scale), in-hospital
death at day 28, days
without organ
dysfunction, days out of
the ICU, mechanical
ventilation-free days, and
days not in hospital at
day 28.

Note. Moderate to severe ARDS was defined by a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of <150
mm Hg with a positive end-expiratory pressure [PEEP] of ≥8 cm of water.
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Appendix C
Table C 1
Outcome Specific Data
Papazian, L., Forel, J., Gacouin, A., Penot-Ragon, C., Perrin, G., Loundou, A., . . . Roch, A. (2010). Neuromuscular Blockers in
Early Acute Respiratory Distress Syndrome. New England Journal of Medicine, 363(12), 1107-1116. doi:10.1056/nejmoa1005372
Death at 28 No. of
days no.
ventilator
(%[95%CI] free days
from day
1 to day
28

No. of
ventilator
free days
from day
1 to day
90

No. of days
without
cardiovascular
failure from
day 1 to day
28

No. of days
without
coagulation
abnormalitie
s from day 1
to day 28

No. of days
without
hepatic
failure
from day 1
to day 28

No. of days
without
renal
failure
from day 1
to day 28

No. of
days
outside
the ICU
from
day 1 to
day 28

No. of
days
outside
the ICU
from day
1 to day
90

Cisatracurium 42 (23.7
Group
[18.1–
30.5])

10.6±9.7

53.1±35.8 18.3±9.4

22.6±8.9

21.3±9.6

20.5±10.1

6.9±8.2

47.7±33.5

Placebo
Group

8.5±9.4

44.6±37.5 16.6±10.4

20.5±9.9

19.1±10.6

18.1±11.6

5.7±7.8

39.5±35.6

0.04

0.03

0.05

0.05

0.05

0.16

0.03

P Value

54 (33.3
[26.5–
40.9])
0.05

Note. Confidence interval (CI). Number (no.).

0.12
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Table C 2
Outcome Specific Data
Peek, G., Elbourne, D., Mugford, M., Tiruvoipati, R., Wilson, A., Allen, E., . . . Truesdale, A. (2010). Randomised controlled trial and
parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult
respiratory failure (CESAR). Health Technology Assessment, 14(35). doi:10.3310/hta14350
Died ≤ 6
months or
died
before
discharge,
no

Died ≤ 6
months or
died
before
discharge,
yes

Cause of
deathRespiratory
Failure

Cause of
deathMultiorgan
failure

Cause of
Cause of
Cause of
deathdeathdeathNeurological Cardiovascular ECMO
related

Median
days in
ICU

Median
days in
hospital

ECMO
group
(N=90)

57

33

8

14

4

1

1

24

35

Control
Group
(N=90)

45

45

24

15

2

3

0

13

17

Note. Sample size (N). Extracorporeal Membrane oxygenation (ECMO).
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Table C 3
Outcome Data Collection
Guérin, C., Reignier, J., Richard, J.-C., Beuret, P., Gacouin, A., Boulain, T., … Ayzac, L. (2013). Prone Positioning in Severe Acute
Respiratory Distress Syndrome. New England Journal of Medicine, 368(23), 2159–2168. doi: 10.1056/nejmoa1214103
Mortality at
day 28
no.(%[95%CI]

Mortality at
day 90
no.(%[95%CI]

Successful
extubation at
day 90 no.(%[95%CI])

Time to
successful
extubation at
day 90
(survivors)
19±21

Time to
successful
extubation at
day 90
(nonsurvivors)
16±11

LOS ICU at
day 90
(survivors)

LOS ICU at
day 90
(nonsurvivors)

Supine
group

75 (32.8
[26.4–38.6])

94 (41.0
[34.6–47.4])

145/223 (65.0
[58.7–71.3])

26±27

18±15

Prone
group

38 (16.0
[11.3–20.7])

56 (23.6
[18.2–29.0])

186/231 (80.5
[75.4–85.6])

17±16

18±14

24±22

21±20

P Value

<0.001

<0.001

<0.001

0.87

0.05

60

Ventilationfree days at
day 28

Ventilationfree days at
day 90

Pneumothorax no. (%[95%CI])

Noninvasive
ventilation at
day 28 -no.
(%[95%CI])

Noninvasive
ventilation at
day 90 -no.
(%[95%CI])

Tracheostomy
at day 28 no./total no.
(% [95% CI])

Supine
group

10±10

43±38

13 (5.7 [3.9–
7.5])

10/212 (4.7
[1.9–7.5])

3/206 (1.5
[0.2–3.2])

12/229 (5.2
[2.3–8.1])

Prone
group

14±9

57±34

15 (6.3 [4.9–
7.7])

4/228 (1.8
[0.1–3.5])

4/225 (1.8
[0.1–3.5])

9/237 (3.8
[1.4–6.0])

P Value

<0.001

<0.001

0.85

0.11

1.00

0.37

Note. Length of Stay (LOS). Confidence Interval (CI). Number (no.).

Tracheostomy
at day 90 no./total no.
(% [95% CI])
18/223 (8.1
[4.5–11.7])

15/235 (6.4
[3.3–9.5])
0.59
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Table C 4
Outcome Data Collection
Combes, A., Hajage, D., Capellier, G., Demoule, A., Lavoué, S., Guervilly, C., . . . Mercat, A. (2018). Extracorporeal Membrane
Oxygenation for Severe Acute Respiratory Distress Syndrome. New England Journal of Medicine, 378(21), 1965-1975.
doi:10.1056/nejmoa1800385
Mortality
at 60
days —
no. (%)

Treatment
failure at
60 days —
no. (%)

Mortality
at 90 days
— no. (%)

Median
length of
stay in
ICU

Median
length of
stay in
hospital

Recruitment Inhaled
Glucocorticoids Prone
maneuvers - nitric oxide - no. (%)
position
or
-no. (%)
no. (%)
prostacyclin
- no. (%)

ECMO
Group
(N=124)

44 (35)

44 (35)

46 (37)

23 (13–
34)

36 (19-48)

27 (22)

75 (60)

80 (65)

82 (66)

Control
Group
(N=125)

57 (46)

72 (58)

59 (47)

18 (8–33)

18 (5-43)

54 (43)

104 (83)

82 (66)

113 (90)

P Value

0.09

<0.001

Note. Sample size (N). Number (no.).
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Table C 5
Outcome Specific Data
Moss, M., Huang, D. T., Brower, R. G., Ferguson, N. D., Ginde, A. A., Gong, M. N., . . . Talmor, D. (2019). Early Neuromuscular
Blockade in the Acute Respiratory Distress Syndrome. New England Journal of Medicine, 380(21), 1997-2008.
doi:10.1056/nejmoa1901686
Inhospital
death by
day 90no. (%)

InDays free
hospital of
death
ventilation
by day
28- no.
(%)

Serious
adverse
eventsno.

Serious
cardiovascular
adverse
events- no.

Atrial
Barotrauma- Pneumothorax Pneumothorax
fibrillation no. (%)
on days 0 to
on days 0 to
or SVT
2- no. (%)
7- no. (%)
during
ICU stayno. (%)

Intervention 213
184
Group
(42.5±2.2) (36.7)

9.6±10.4

35

14

101 (20.2)

20 (4.0)

8 (1.6)

14 (2.8)

Control
Group

216
187
(42.8±2.2) (37.0)

9.9±10.9

22

4

99 (19.6)

32 (6.3)

10 (2.0)

25 (5.0)

P Value

0.93

0.09

0.02

0.88

0.12

0.81

0.10

Note. Supraventricular Tachycardia (SVT). Number (no.).
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Appendix D 1
Papazian, L., Forel, J., Gacouin, A., Penot-Ragon, C., Perrin, G., Loundou, A., . . . Roch, A.
(2010). Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. New
England Journal of Medicine, 363(12), 1107-1116. doi:10.1056/nejmoa1005372
Section A: Are the results of the trial valid?

Yes

1. Did the trial address a clearly focused issue

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for?
4. Were patients, healthcare workers and study
personnel ‘blind’ to treatment?
5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the
groups treated equally? With one exception in the
conventional arm. One patient was put on an experimental
form of lung support, known as Novalung, which violated the
protocol.
Section B: What are the results?

No

Can’t
Tell

No

X
X
X
X

7. How large was the treatment effect? The 90-day
mortality in the cisatracurium group was 31.6% (56 patients)
and 40.7% (66 patients) in the placebo group.
8. How precise was the estimate of treatment effect? The
cisatracurium group had an absolute reduction of 9% in
mortality at day 90 or discharge. The sample size of this study
was based on comparisons to two earlier groups. Since the
mortality of the placebo group in this study was lower than
that of the control group in earlier studies, this study was
underpowered. 855 patients would have been required to
produce an 80% statistical power.
Section C: Will the results help locally?
Yes
9. Can the results be applied to the local population, or
in your context?
10. Were all the clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

Can’t
Tell

X
X
X
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Appendix D 2
Peek, G., Elbourne, D., Mugford, M., Tiruvoipati, R., Wilson, A., Allen, E., . . . Truesdale,
A. (2010). Randomised controlled trial and parallel economic evaluation of conventional
ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory
failure (CESAR). Health Technology Assessment, 14(35). doi:10.3310/hta14350
Section A: Are the results of the trial valid?
Yes
Can’t
No
Tell
1. Did the trial address a clearly focused issue

X

2. Was the assignment of patients to treatments
randomized?

X

3. Were all of the patients who entered the trial
properly accounted for? Three patients in the conventional
arm declined permission for follow up.
4. Were patients, healthcare workers and study
personnel ‘blind’ to treatment? Non-blinded to clinicians.
Blinded to researchers at six-month follow up.
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the
groups treated equally?

X
X
X
X

Section B: What are the results?
7. How large was the treatment effect? Mortality in the
ECMO arm was lower than the conventional arm, however it
did not reach statistical significance.
8. How precise was the estimate of treatment effect?
Original power calculations were based on anticipated 70%
mortality prediction in the control group. The researchers
considered a 10% chance of severe disability in both arms
and determined 240 total patients were required. Sample size
review conducted in 2003 revealed only 60% of target size
was obtained. It was agreed that a lower sample size of 180
patients would be enough to detect a reduction by 1/3.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or
in your context?

X

10. Were all the clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X

Can’t
Tell

No
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Appendix D 3
Guérin, C., Reignier, J., Richard, J.-C., Beuret, P., Gacouin, A., Boulain, T., … Ayzac, L.
(2013). Prone Positioning in Severe Acute Respiratory Distress Syndrome. New England
Journal of Medicine, 368(23), 2159–2168. doi: 10.1056/nejmoa1214103
Section A: Are the results of the trial valid?

Yes

1. Did the trial address a clearly focused issue

X

2. Was the assignment of patients to treatments
randomized?

X

3. Were all of the patients who entered the trial
properly accounted for?

X

Can’t
Tell

4. Were patients, healthcare workers and study
personnel ‘blind’ to treatment? Blinding of outcome
assessors.
5. Were the groups similar at the start of the trial? One
X
exception is that the SOFA score was uneven, with the mean
supine group measuring 10.4±3.4 and 9.6±3.2 in the prone
group.
6. Aside from the experimental intervention, were the
groups treated equally? Two interventions used were
unevenly distributed. Use of vasopressors (supine 83% and
prone 72.6%) and neuromuscular blockers (supine 82.3% and
prone 91%).
Section B: What are the results?
7. How large was the treatment effect? The prone group
had a 51% relative reduction and 17% absolute reduction in
28-day mortality compared to the supine group.
8. How precise was the estimate of treatment effect? An
estimated sample of 456 patients would generate a 90%
power to detect an absolute reduction of 15 percentage points
with prone positioning.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or
in your context?

X

10. Were all the clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X

No

X

X

Can’t
Tell

No
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Appendix D 4
Combes, A., Hajage, D., Capellier, G., Demoule, A., Lavoué, S., Guervilly, C., . . .
Mercat, A. (2018). Extracorporeal Membrane Oxygenation for Severe Acute Respiratory
Distress Syndrome. New England Journal of Medicine, 378(21), 1965-1975.
doi:10.1056/nejmoa1800385
Section A: Are the results of the trial valid?
1. Did the trial address a clearly focused issue
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for?
4. Were patients, healthcare workers and study
personnel ‘blind’ to treatment? Medical and nursing
staff not blinded, participants not blinded. Research staff
members were blinded
5. Were the groups similar at the start of the trial?

Yes

Can’t
Tell

X
X
X
X

X

6. Aside from the experimental intervention, were the
groups treated equally? Not all of the patients who
received ECMO received the therapy in an ECMO center.
Section B: What are the results?
7. How large was the treatment effect? At day 60,
mortality in the ECMO group was 35% compared to 46%
in the control group. 60-day mortality was not
significantly lower in the ECMO group.
8. How precise was the estimate of treatment effect? At
an alpha level of 5% and with group-sequential analysis
after randomization of 60 patients, the maximum sample
would need to be 331 to have an 80% power. At the fourth
planned sequential interim analysis, the trial was stopped
in accordance with prespecified rules, leaving 249
patients included in the trial.
Section C: Will the results help locally?
9. Can the results be applied to the local population, or
in your context?
10. Were all the clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

No

X

Yes

Can’t
Tell

No

X
X
X
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Appendix D 5
Moss, M., Huang, D. T., Brower, R. G., Ferguson, N. D., Ginde, A. A., Gong, M. N., . . .
Talmor, D. (2019). Early Neuromuscular Blockade in the Acute Respiratory Distress
Syndrome. New England Journal of Medicine, 380(21), 1997-2008.
doi:10.1056/nejmoa1901686
Section A: Are the results of the trial valid?
Yes
Can’t
No
Tell
1. Did the trial address a clearly focused issue
X
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for?

X
X

4. Were patients, healthcare workers and study
personnel ‘blind’ to treatment?

X

5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the
groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect? At day 90, any
cause of in-hospital death occurred in 213 patients
(42.5%) in the cisatracurium group and 216 patients
(42.8%) in the control group (P=0.93)
8. How precise was the estimate of treatment effect? At
a two-sides alpha level of 0.05, it was calculated that
1408 patients would need to be studied in order for the
trial to have 90% statistical power. 1006 patients were
included, however, by the second interim analysis, the
trial was stopped for futility.
Section C: Will the results help locally?

Yes

9. Can the results be applied to the local population, or
in your context?

X

10. Were all the clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

Can’t
Tell

X

No
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Appendix E
Cross Study Analysis
Author, Year
28
1

Papazian et
al., 2010

Cisatracurium
Group: 23.7%

Mortality Rate at Day:
60

90

Median Length of Stay (LOS) in Days
ICU
Hospital

Not Reported

Not Reported

Not Reported

Not Reported

Not Reported

Not Reported

ECMO Group: 24

ECMO Group: 35

Control Group:13

Control Group: 17

Prone Group: 24±22

Not Reported

Control
Group:33.3%
P= 0.05
2
3

4

Peek et al.,
2010

Not Reported

Guérin et al.,
2013

Prone Group:
16.0%

Prone Group:
23.6%

Control Group:
32.8%

Control Group:
41.0%

P= <0.001

P= <0.001

Not Reported

ECMO
Group: 35%

ECMO
Group:37%

Control Group:
46%

Control Group:
47%

Combes et al.,
2018

P= 0.09

Not Reported

Control Group: 26±27
P= 0.05
ECMO Group: 23

ECMO Group: 36

Control Group: 18

Control Group: 18
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5

Moss et al.,
2019

Cisatracurium
Group: 36.7%
Control Group:
37.0 %

Not Reported

Cisatracurium
Group: 213
(42.5±2.2)
Control Group:
216 (42.8±2.2)
P= 0.93

Not Reported

Not Reported
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